Conexeu Sciences (CNXU)
Market Price (9/21/2026): $4.89 | Market Cap: $-Sector: Health Care | Industry: Biotechnology
Conexeu Sciences (CNXU)
Market Price (9/21/2026): $4.89Market Cap: $-Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Weak multi-year price returns2Y Excs Rtn is -102%, 3Y Excs Rtn is -137% | High stock price volatilityVol 12M is 139% Key risksCNXU key risks include [1] significant uncertainty in securing regulatory approval and commercial viability for its preclinical CXU™ scaffold device, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -102%, 3Y Excs Rtn is -137% |
| High stock price volatilityVol 12M is 139% |
| Key risksCNXU key risks include [1] significant uncertainty in securing regulatory approval and commercial viability for its preclinical CXU™ scaffold device, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Conexeu Sciences (CNXU) stock has lost about 60% since 5/31/2026 because of the following key factors:
1. Direct Listing and Subsequent Share Dilution.
Conexeu Sciences went public through a direct listing on May 21, 2026, registering 9.5 million resale shares without generating new capital. This created an imbalance between supply and demand, contributing to a 27.0% stock price decrease from $14.40 on May 23, 2026, to $10.51 by July 16, 2026. Additionally, the company issued 1,448,368 unregistered shares and 202,500 unregistered common stock purchase warrants between June 18, 2026, and September 4, 2026. These issuances, including 762,608 shares from warrant exercises on September 4, 2026, at $2.30 per share (generating $1.75 million), increased the total common shares outstanding to 28.2 million by September 10, 2026, diluting existing shareholders.
2. Significant Operating Losses and "Going Concern" Risk.
The company reported substantial losses, with a net loss of $7.7 million for fiscal Q3 2026 (ended July 31, 2026), a considerable increase from $1.3 million in the comparable period of the previous fiscal year. For the nine months ended July 31, 2026, the net loss reached $11.7 million, up from $2.0 million year-over-year, culminating in an accumulated deficit of $16.3 million. Conexeu explicitly disclosed "substantial doubt about its ability to continue as a going concern" without securing additional financing. As of July 31, 2026, cash and cash equivalents stood at a low $1.97 million, with net cash used in operating activities at $10.1 million for the nine months ended July 31, 2026.
Show more
Conexeu Sciences (CNXU) stock has lost about 60% since 5/31/2026 because of the following key factors:
1. Direct Listing and Subsequent Share Dilution.
Conexeu Sciences went public through a direct listing on May 21, 2026, registering 9.5 million resale shares without generating new capital. This created an imbalance between supply and demand, contributing to a 27.0% stock price decrease from $14.40 on May 23, 2026, to $10.51 by July 16, 2026. Additionally, the company issued 1,448,368 unregistered shares and 202,500 unregistered common stock purchase warrants between June 18, 2026, and September 4, 2026. These issuances, including 762,608 shares from warrant exercises on September 4, 2026, at $2.30 per share (generating $1.75 million), increased the total common shares outstanding to 28.2 million by September 10, 2026, diluting existing shareholders.
2. Significant Operating Losses and "Going Concern" Risk.
The company reported substantial losses, with a net loss of $7.7 million for fiscal Q3 2026 (ended July 31, 2026), a considerable increase from $1.3 million in the comparable period of the previous fiscal year. For the nine months ended July 31, 2026, the net loss reached $11.7 million, up from $2.0 million year-over-year, culminating in an accumulated deficit of $16.3 million. Conexeu explicitly disclosed "substantial doubt about its ability to continue as a going concern" without securing additional financing. As of July 31, 2026, cash and cash equivalents stood at a low $1.97 million, with net cash used in operating activities at $10.1 million for the nine months ended July 31, 2026.
3. Pre-revenue Stage and Delayed Commercialization.
Conexeu Sciences is a pre-revenue biotechnology company that relies entirely on its lead device candidate, CXU. The anticipated 510(k) submission to the U.S. Food and Drug Administration (FDA), crucial for commercialization, has been delayed to fiscal Q1 2027 (January 1 to March 31, 2027), from an earlier projected date of June 30, 2026. This extended timeline to potential market entry and revenue generation has contributed to investor uncertainty. Conexeu's fiscal year ends on October 31.
4. Increased Bearish Sentiment and Short Interest.
Bearish sentiment toward Conexeu Sciences intensified during the period, reflected by a significant 56.4% increase in short interest during August 2026. This indicates a growing number of investors betting against the stock, suggesting a negative outlook on the company's near-term prospects and valuation.
Show less
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
5/31/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| CNXU | -57.7% | |
| Market (SPY) | 0.9% | 12.0% |
| Sector (XLV) | 12.7% | -14.3% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| CNXU | ||
| Market (SPY) | 11.6% | 10.5% |
| Sector (XLV) | 5.5% | -18.4% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 9/20/2026| Return | Correlation | |
|---|---|---|
| CNXU | ||
| Market (SPY) | 19.4% | 10.5% |
| Sector (XLV) | 24.1% | -18.4% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2023 to 9/20/2026| Return | Correlation | |
|---|---|---|
| CNXU | ||
| Market (SPY) | 75.6% | 10.5% |
| Sector (XLV) | 32.3% | -18.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CNXU Return | - | - | - | - | - | -63% | -63% |
| Peers Return | -3% | -44% | 78% | -2% | -24% | 31% | -6% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| CNXU Win Rate | - | - | - | - | - | 0% | |
| Peers Win Rate | 52% | 33% | 60% | 47% | 38% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| CNXU Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -50% | -59% | -42% | -46% | -57% | -45% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IART, ORGO, MDXG, VCEL, RCEL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
CNXU has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
CNXU has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Conexeu Sciences (CNXU)
Conexeu Sciences (CNXU) is an early-stage medical device company focused on developing a new class of collagen-based regenerative tissue products. The company was formed to acquire and commercialize intellectual property developed over a decade at the University of British Columbia, specializing in advanced solutions for tissue repair.
The company's primary product candidate is the CXU™ scaffold device, also known as "10 Minute Tissue™." This innovative product is a temperature-responsive, collagen-based extracellular matrix (ECM) formulation designed to transition from a liquid to a gel-like scaffold within approximately ten minutes of topical application or injection. The CXU™ scaffold is currently in preclinical development, where it is being evaluated for its ability to support cellular infiltration, vascularization, and organized tissue remodeling.
Conexeu Sciences intends to target the wound care market and other medical applications with its CXU™ scaffold. The company plans to seek U.S. Food and Drug Administration (FDA) 510(k) clearance for the device as a Class II medical device, aiming to make it commercially available to healthcare providers and patients in need of advanced regenerative tissue solutions.
AI Analysis | Feedback
Here are 1-2 brief analogies for Conexeu Sciences (CNXU):
- An early-stage Organogenesis focused on developing a new type of collagen-based regenerative tissue for wound care.
- Like an early-stage Integra LifeSciences developing a novel regenerative medical device for tissue repair.
AI Analysis | Feedback
- CXU™ scaffold device candidate: A temperature-responsive, collagen-based extracellular matrix (ECM) formulation designed to transition from a liquid to a gel-like scaffold for regenerative tissue applications.
AI Analysis | Feedback
Based on the provided company description, Conexeu Sciences (CNXU) is an early-stage medical device company with its only device candidate, CXU™ scaffold, currently in preclinical development. The device has not been approved or cleared for marketing in any jurisdiction, and the company is still conducting preclinical research and preparing for regulatory engagement.
Therefore, Conexeu Sciences does not currently have any major customers, as its products are not yet commercially available.
AI Analysis | Feedback
AI Analysis | Feedback
Miles Harrison
President & Chief Executive Officer
Mr. Harrison was appointed President and Chief Executive Officer of Conexeu Sciences in November 2025. He is a healthcare and aesthetics executive with a history of scaling global businesses, driving innovation, and creating shareholder value. Previously, Mr. Harrison co-founded and led Novaestiq Corp., building a novel aesthetics platform and positioning it for a significant strategic exit in 2025, with Novaestiq Corp. being acquired by Waldencast plc. Before Novaestiq, he served as President & General Manager, North America at Galderma, leading three business units across North America and supporting EQT's multi-billion dollar acquisition of Galderma in late 2019. Earlier in his career, he built the U.S. Consumer Business Unit at Nestlé Skin Health from the ground up. Mr. Harrison currently serves on the Board of Castle Biosciences (NASDAQ: CSTL).
Steve Inouye
Chief Financial Officer, Corporate Secretary and Treasurer
Mr. Inouye was appointed Chief Financial Officer for Conexeu Sciences in November 2023, and subsequently also assumed the positions of Secretary and Treasurer in April 2025. He is a financial executive with nearly 40 years of experience, primarily focused on accounting and tax management, while also providing strategic guidance to both private and publicly held companies. Mr. Inouye co-founded a Canadian biotech company that developed bio-pharmaceutical products and possesses deep expertise in small-cap markets, securities regulations, and corporate governance. He has managed audits for multiple go-public transactions, supporting capital raises and growth initiatives.
Dr. Claudia Chavez-Munoz, MD, PhD
Chief Scientific Officer, Co-Founder
Dr. Chavez-Munoz is a distinguished surgeon-scientist, internationally recognized for her pioneering work in burn care, wound healing, and tissue regeneration. She is a co-founder of Conexeu Sciences, established in 2023, and currently serves as Chief Scientific Officer, leading innovation in regenerative therapeutics. Prior to her current role, Dr. Chavez-Munoz served as the company's Chief Medical Officer from October 2023 to April 2025.
Dr. Brian Pilcher, PhD
Chief Medical Officer
Dr. Pilcher was appointed Chief Medical Officer for Conexeu Sciences in April 2025.
Sonia Thomas, MBA
Head of Strategy & Transformation
Ms. Thomas brings over 20 years of experience in operational excellence, brand development, M&A integration, finance, and commercial growth, with a background spanning Fortune 500 and global healthcare organizations. Her experience includes multiple positions at Galderma in Marketing, Finance, Project Management, Launch Excellence, and Commercial Strategy. Her earlier career involved leadership roles in audit, finance, integration, and operations across financial services and investment banking.
AI Analysis | Feedback
-
Regulatory Approval and Commercialization Uncertainty for its Sole Product Candidate: Conexeu Sciences faces significant uncertainty regarding the regulatory approval and commercialization of its only device candidate, the CXU™ scaffold device. The device is currently in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The U.S. Food and Drug Administration (FDA) has not yet determined the appropriate classification or regulatory pathway for the device candidate, may require additional data or a different pathway, and there is no assurance that the company will obtain clearance or that the device candidate will become commercially available.
-
Sole Reliance on a Single Device Candidate: The company's business is entirely dependent on the successful development and commercialization of its CXU™ scaffold device candidate. The provided information explicitly states that "The Company's only device candidate is the CXU™ scaffold device candidate". This means that if the CXU™ device fails to achieve regulatory approval, commercial viability, or market acceptance, the company currently has no other product in its pipeline to pursue, posing a significant risk to its future operations and success.
AI Analysis | Feedback
AI Analysis | Feedback
The addressable markets for Conexeu Sciences' CXU™ scaffold device are as follows:
- The U.S. advanced wound care market was valued at approximately USD 5.3 billion in 2025 and is projected to reach USD 8.6 billion by 2034.
- The wound healing segment of the global regenerative medicine market was estimated at USD 10.32 billion in 2024 and is projected to grow to approximately USD 36.84 billion by 2030. North America is a dominant region in the regenerative medicine market, holding over 48% market share in 2025.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Conexeu Sciences (CNXU) over the next 2-3 years:
- Successful attainment of U.S. Food and Drug Administration (FDA) 510(k) clearance for the CXU™ scaffold device.
- Initial commercialization and market introduction of the CXU™ scaffold device in the U.S. wound care market.
- Expansion into additional medical applications for the CXU™ scaffold device beyond initial wound care uses.
- Geographic market expansion of the CXU™ scaffold device into territories outside the United States.
AI Analysis | Feedback
Share Repurchases
- Conexeu Sciences has not made any share repurchases.
Share Issuance
- On May 12, 2026, Conexeu Sciences issued 4,342,648 shares of common stock upon the exercise of outstanding warrants, resulting in gross proceeds of approximately $1.96 million.
- In 2025, the company issued 3,750,000 shares through a private placement that closed on May 16, 2025, and 397,789 shares from a Regulation Crowdfunding (Reg CF) offering completed in September or October 2025.
- In September 2024, 750,000 shares of common stock were issued as part of a debt settlement agreement.
Inbound Investments
- Conexeu Sciences completed a $5 million Regulation Crowdfunding (Reg CF) financing in October 2025.
- Approximately $7 million was deployed developing the company's technology over more than a decade, including funds from universities, government grants, and existing shareholders.
Capital Expenditures
- For the three months ended January 2026, Conexeu Sciences reported capital expenditures of $0.01 million for the purchase of property, plant, and equipment.
- Funds raised from financing are intended to accelerate the development and commercialization of its patented collagen platform, specifically for 510(k) regulatory clearances and product development.
Peer Outperformance in Biotechnology
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.2% | 43.2% | 90.1% | CAH 392% · MCK 346% · COR 168% |
| Managed Health Care | 8 | 40.4% | -5.3% | 2.3% | OSCR 84% · HQY 56% · ELV 17% |
| Health Care Services | 20 | 21.1% | 37.6% | -0.3% | HIMS 239% · RDNT 173% · DGX 76% |
| Health Care Facilities | 24 | 6.0% | 6.5% | -4.5% | NHC 271% · THC 261% · ENSG 129% |
| Health Care Equipment | 50 | -2.7% | -0.2% | -21.1% | POCI 11050% · UFPT 341% · GKOS 222% |
| Pharmaceuticals | 62 | -10.5% | 14.8% | -38.6% | LQDA 2472% · INDV 1099% · ETON 1051% |
| Health Care Supplies | 12 | 14.1% | -8.9% | -39.7% | LNTH 287% · HAE 54% · MMSI 20% |
| Life Sciences Tools & Services | 109 | 4.3% | -11.3% | -68.4% | SNWV 1757% · MEDP 231% · NTRA 199% |
| Health Care Technology | 21 | -25.8% | -52.6% | -79.2% | SPOK 68% · HSTM 3% · VEEV -13% |
| Biotechnology ← | 364 | 0.6% | -21.7% | -79.4% | CELZ 1280% · DNTH 1221% · ELVN 1069% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.99 |
| Mkt Cap | 0.7 |
| Rev LTM | 355 |
| Op Inc LTM | 9 |
| FCF LTM | 21 |
| FCF 3Y Avg | 8 |
| CFO LTM | 46 |
| CFO 3Y Avg | 52 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.6% |
| Rev Chg 3Y Avg | 6.6% |
| Rev Chg Q | 0.8% |
| QoQ Delta Rev Chg LTM | 0.2% |
| Op Inc Chg LTM | 24.6% |
| Op Inc Chg 3Y Avg | 73.0% |
| Op Mgn LTM | 2.5% |
| Op Mgn 3Y Avg | 1.6% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 7.0% |
| CFO/Rev 3Y Avg | 6.2% |
| FCF/Rev LTM | 4.6% |
| FCF/Rev 3Y Avg | 0.5% |
Price Behavior
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.31 | 2.40 | 0.73 | 1.33 | 0.36 | 0.42 |
| Up Beta | 9.65 | 9.23 | 0.69 | -0.20 | -4.04 | 1.36 |
| Down Beta | -13.56 | -1.38 | 0.93 | -1.67 | 3.40 | 1.09 |
| Up Capture | -228% | -82% | -48% | -43% | -20% | -2% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 10 | 19 | 29 | 30 | 30 | 30 |
| Down Capture | -43% | 222% | 173% | 103% | 65% | 36% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 11 | 23 | 35 | 38 | 38 | 38 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CNXU | |
|---|---|---|---|---|
| CNXU | -65.7% | 138.8% | -1.74 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | -18.4% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 10.5% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 2.2% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | -1.5% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | -15.7% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | -12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CNXU | |
|---|---|---|---|---|
| CNXU | -19.2% | 138.8% | -1.74 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | -18.4% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 10.5% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 2.2% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | -1.5% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | -15.7% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | -12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CNXU | |
|---|---|---|---|---|
| CNXU | -10.1% | 138.8% | -1.74 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | -18.4% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 10.5% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 2.2% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | -1.5% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | -15.7% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | -12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Insider Activity
Updated 9/9/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Purcell, Lynn Sebastian | OnePointTwo Capital Ventures LLC | Buy | 6232026 | 0.80 | 202,500 | 162,000 | 2,187,392 | Form | |
| 2 | Onepointtwo, Capital Ventures Llc | Direct | Buy | 5142026 | 0.80 | 422,500 | 338,000 | 838,000 | Form | |
| 3 | Purcell, Lynn Sebastian | OnePointTwo Capital Ventures LLC | Buy | 5142026 | 0.80 | 422,500 | 338,000 | 2,025,392 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Purcell, Lynn Sebastian | OnePointTwo Capital Ventures LLC | Buy | 6232026 | 0.80 | 202,500 | 162,000 | 2,187,392 | Form | |
| 2 | Onepointtwo, Capital Ventures Llc | Direct | Buy | 5142026 | 0.80 | 422,500 | 338,000 | 838,000 | Form | |
| 3 | Purcell, Lynn Sebastian | OnePointTwo Capital Ventures LLC | Buy | 5142026 | 0.80 | 422,500 | 338,000 | 2,025,392 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.